TP53 and B-cell non-Hodgkin lymphoma: Its cytotoxicity was mainly effective in TP53‐mutated or PTEN‐deleted lymphomas strengthening the hypothesis of AF repurposing for treatment of TP53‐mutated or PTEN‐deleted refractory B‐cell lymphoma.